Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 11 of the 20 sources its claims cite were checked for support.

Utilization of a Meningitis/Encephalitis PCR panel at the University Hospital Basel – a retrospective study to develop a diagnostic decision rule

Open access
Erba, Andrea, Franzeck, Fabian C., Hinic, Vladimira, Egli, Adrian, Osthoff, Michael · 2024 · Frontiers in Medicine

Abstract

Background: Meningitis/Encephalitis (ME) PCR panel covers 14 viral, bacterial, and fungal pathogens and has been implemented in many institutions worldwide. Post-marketing studies indicate a reduced sensitivity and overutilization underscoring the need for a more targeted usage. The aim of our study is to describe the utilization of the ME panel and to develop a diagnostic-stewardship based decision rule. Materials: Adult patients, who underwent CSF analysis with the ME panel between August 2016 and June 2021 at the University Hospital Basel, were included. Demographic, clinical, microbiological, and laboratory data were extracted from the electronic health record. Factors associated with a positive ME panel result were identified, and a decision rule was developed to potentially optimize the diagnostic yield and reduce the number of unnecessary tests. Results: (19%), Enterovirus (16%), Herpes simplex Virus 1/2 (16%), and Human Herpesvirus 6 (HHV-6, 13%). Fever, vomiting, headache, and photophobia were more frequently present in test positive patients as were significantly higher CSF leukocytes and protein concentrations. When simulating a decision rule based on CSF leukocytes and protein concentration, only 35% of all patients would have qualified for a ME panel tests, thereby increasing the positivity rate to 22.7%. 10 of 106 positive ME panels would have been missed, only involving HHV-6 and VZV (6 and 4 cases, respectively). As these subjects were either severely immunocompromised or had clinical features of shingles we propose extending the testing algorithm by including those criteria. Conclusion: The ME panel positivity rate at our institution was similar as previously published. Our results highlight the need for diagnostic-stewardship interventions when utilizing this assay by implementing a stepwise approach based on a limited number of clinical and laboratory features. This decision rule may improve the pretest probability of a positive test result, increase the quality of test utilization, and reduce costs.

Overview

CoChat Summary

## TL;DR

This retrospective single-center study found that the Biofire FilmArray ME PCR panel was used broadly at University Hospital Basel but had a positive rate of only 8.6% (106/1,236). The authors propose a decision rule based on CSF leukocytes and protein, which would have reduced testing to 35% of patients and increased the positivity rate to 22.7%, while missing 10 positive panels.

## Key findings

  • Among 1,236 adult patients who received at least one ME panel, 106 were positive, for a positivity rate of 8.6% (95% CI 7.1–10.3%).
  • The most frequent detected pathogens were VZV (29/106, 27.4%), Streptococcus pneumoniae (20/106, 18.9%), Enterovirus (17/106, 16%), HSV-1/2 (17/106, 16%), and HHV-6 (14/106, 13.2%).
  • Fever, vomiting, headache, and photophobia were more common in test-positive patients, and CSF leukocytes and protein were significantly higher (p < 0.001).
  • A rule using CSF leukocytes ≥10 × 10^6/L or CSF protein ≥1,000 mg/L would have qualified 423/1,194 patients (35%) for testing, raising the positivity rate to 96/423 (22.7%) and yielding a sensitivity of 90.6% (95% CI 83.3–95.4%) for detecting any pathogen.
  • Under that rule, 10/106 positive results would have been missed; these were mainly HHV-6 (6 cases) and VZV (4 cases), and the authors note the missed cases were either immunosuppressed or had shingles-like clinical features.

## Methods

  • Retrospective observational study at a single 700-bed teaching hospital in north-western Switzerland, including adult in- and outpatients (≥18 years) who underwent lumbar puncture with ME panel testing from August 2016 to June 2021.
  • Data were extracted from electronic clinical and microbiological records, including demographic, clinical, microbiological, laboratory, and discharge-summary information; patients without sufficient records, with data refusal, or with repeated panels in the same admission/outpatient period were excluded.
  • The analysis compared positive vs negative ME panels using chi-squared and Mann–Whitney U tests, then simulated a diagnostic decision rule based on limited clinical/laboratory features, especially CSF leukocytes and protein.

## Limitations

  • The paper explicitly states limitations of retrospective, single-center design; absence of singleplex PCRs as a gold standard; unknown exact number of immunocompromised patients; lack of the proportion of patients with suspected CNS infection who underwent lumbar puncture; no analysis of lumbar puncture indications; keyword-based symptom extraction; and no validation cohort.
  • Evident from the text: the proposed decision rule was only simulated on the same dataset and was not prospectively validated, so its real-world safety and performance remain unproven.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fmed.2024.1351903

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Decision rule for the use of the ME panel.
Figure 1 Decision rule for the use of the ME panel.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 1 Not valid · 2 Not checked · 31 Own results and interpretations

20 more claims

Create a free account to see all 42 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 5
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 15

Metadata

Authors
Erba, A., Franzeck, F. C., Hinic, V., Egli, A., & Osthoff, M.
Affiliations
  • University Hospital of Basel (CH)
  • University of Zurich (CH)
Corresponding author
Osthoff, Michael
Venue
Frontiers in Medicine
Published
2024-04-17
Volume
11
Pages
1351903-1351903
ISSN
2296-858X (ISSN-L)
OpenAlex
W4394888059
Cited by
15
References
31
Citations by year
2026: 4 · 2025: 8 · 2024: 3
FWCI
5.16
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Keywords
diagnostic decision rules, diagnostic stewardship, cerebrospinal fluid analysis, CSF protein concentration, test utilization, unnecessary testing, herpes simplex virus, human herpesvirus 6, varicella-zoster virus, immunocompromised patients, herpes zoster, pretest probability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Utilization of a Meningitis/Encephalitis PCR panel at the University Hospital Basel – a retrospective study to develop a diagnostic decision rule. https://app.cochat.ai/papers/10.3389/fmed.2024.1351903
The paper
Erba, A., Franzeck, F. C., Hinic, V., Egli, A., & Osthoff, M. (2024). Utilization of a Meningitis/Encephalitis PCR panel at the University Hospital Basel – a retrospective study to develop a diagnostic decision rule. Frontiers in Medicine. https://doi.org/10.3389/fmed.2024.1351903

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.